Revalesio’s Drug Shows Promise in Treating Alzheimer’s
News Oct 21, 2014
Revalesio Corporation and Rush University Medical Center’s Department of Neurological Sciences published findings from two research studies that demonstrate the potential for RNS60 to treat Alzheimer’s disease and other forms of dementia by protecting neuronal function, restoring neuronal connections and promoting neuronal plasticity.
RNS60 is a therapeutic saline containing highly potent charge-stabilized nanostructures (CSNs) that decrease inflammation and cell death. Revalesio demonstrated the ability of RNS60 to reduce the inflammatory responses linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases. The company’s latest research with Rush University Medical Center investigated the potential application of RNS60 for treating Alzheimer’s disease and other forms of dementia.
“The impact of RNS60 on Alzheimer’s disease as outlined in our studies presents new opportunities for hope and deeper research in treating a disease that currently cannot be prevented, cured or even successfully managed,” said Dr. Kalipada Pahan, Professor of Neurological Sciences, Biochemistry and Pharmacology and the Floyd A. Davis, M.D., Endowed Chair of Neurology at the Rush University Medical Center. “Our findings sparked tremendous excitement for RNS60, identifying an opportunity for advanced research to develop a novel treatment to help the rapidly increasing number of Alzheimer’s disease and dementia patients.”
“Early RNS60 results from in vitro research and animal studies, coupled with high tolerability experience for both the inhaled and injectable formulations, are very promising and encouraging for all of us at Revalesio. There are multiple projects underway that will help validate and expand our understanding of RNS60,” said Bert van den Bergh, President of Revalesio Corporation and former President of Neuroscience Products at Eli Lilly & Company. “Dr. Pahan’s impressive results have also motivated us to accelerate our initial human proof of concept studies so we can determine initial efficacy and safety in people with Alzheimer’s disease. Our scientific team is giving this their highest priority and we look forward to working with various collaborators and partners around the globe to move RNS60 forward rapidly toward a possible use in Alzheimer’s disease.”
Alzheimer’s disease is characterized by the presence of neuritic plaques composed of amyloid-β (Aβ) protein, neurofibrillary tangles composed of hyperphosphorylated tau protein and extensive neuronal cell death. The initial Rush University Medical Center study examined the effects of RNS60 against these factors in a transgenic animal model of Alzheimer’s disease. The results establish RNS60 as a means to suppress neuronal loss, attenuate tau phosphorylation and protect memory functions in animal models with advanced Alzheimer’s disease.
Rush University Medical Center then conducted a second study to determine the impact of RNS60 on neuronal plasticity, which is damaged by Alzheimer’s disease. The results identified enhanced morphological plasticity in hippocampal neurons after treatment with RNS60, which could lead to restored learning and memory functions for Alzheimer’s patients.
1 in 3 U.S. Adults May Be Using Medications That Have Potential to Cause DepressionNews
A new study from University of Illinois at Chicago researchers suggests that more than one-third of U.S. adults may be using prescription medications that have the potential to cause depression or increase the risk of suicide.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018